Regenxbio's RGX-121 gene therapy for Hunter syndrome is the main catalyst, with FDA approval targeted for February 2026.

Rocket Pharmaceuticals, Inc. ( NASDAQ: RCKT) Morgan Stanley 23rd Annual Global Healthcare Conference September 9, 2025 9:15 AM EDT ...

Vector is expanding its portfolio with SDx Cloud, a platform for developing software-defined systems and integrating ...

NVIDIA has introduced its AI Blueprint for 3D object generation, giving artists a streamlined way to create up to 20 assets ...